(Q38746822)

6 September 2017

1 reference

title

Estrogen replacement and cardiovascular disease: serum lipids and blood pressure effects (English)

1 reference

6 September 2017

main subject

cardiovascular disease

1 reference

Hazzard WR

1

1 reference

6 September 2017

language of work or name

English

0 references

publication date

1 December 1989

1 reference

American Journal of Obstetrics and Gynecology

6 September 2017

published in

1 reference

6 September 2017

volume

161

1 reference

6 September 2017

issue

6 Pt 2

1 reference

6 September 2017

page(s)

1847-1853

1 reference

Hypertension. Relationship with other risk factors

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Status of risk factors and their consideration in antihypertensive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Hypertension and other risk factors in coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Multivariate Analysis of Risk Factors for Coronary Heart Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Antihypertensive therapy and lipids. Evidence, mechanisms, and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10 000 men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Cardiovascular effects of endogenous and exogenous sex hormones over a woman's lifetime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Estrogen use and cardiovascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Estrogen replacement therapy and protection from acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

A prospective study of postmenopausal estrogen therapy and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

The effect of type and dose of oestrogen on the blood pressure of post-menopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Long-term estrogen substitution and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Cardiovascular risk and use of estrogens or estrogen-progestagen combinations. Stanford three-community study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

The Effect of Conjugated Estrogens on the Renin-Angiotensin System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Estrogen use, hypertension and stroke in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Heart Disease Risk Factors and Hormone Use in Postmenopausal Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Characteristics of estrogen-treated women. A descriptive epidemiological study of a Swedish population. Part II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Menopause and coronary heart disease. The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Biological Effects of Various Doses of Conjugated Equine Estrogens in Postmenopausal Women*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Tamoxifen and natural progesterone as supplements to low-dose postmenopausal estrogen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

The effect of various regimens of hormone therapy on serum cholesterol and triglyceride concentrations in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

A continuous estrogen-progestogen regimen for climacteric complaints. Effects on lipid and lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Estrogen Replacement Therapy II: A Prospective Study in the Relationship to Carcinoma and Cardiovascular and Metabolic Problems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Postmenopausal estrogen and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Myocardial infarction and estrogen therapy in post-menopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Coronary risk and estrogen use in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Noncontraceptive estrogens and nonfatal myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Menopausal oestrogen therapy and protection from death from ischaemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Use of postmenopausal hormones and risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Estrogen use and myocardial infarction risk: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

The effects of long-term estrogen on hysterectomized women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Postmenopausal estrogen use and heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980005-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9378(89)80005-5

1 reference

6 September 2017

1 reference